Recent FDA Actions

By Ted Rosen RUXOLITINIB 1.5% CREAM (Opzelura, Incyte Dermatology) is already approved for the treatment of mild to moderate atopic dermatitis. The FDA has accepted a priority supplemental New Drug Application (sNDA) for the same agent for use in vitiligo. This is based on the results of two phase 3 trials where twice daily application […]